NEW YORK – The US Food and Drug Administration granted accelerated approval on Thursday to Epizyme's tazemetostat (Tazverik) for relapsed or refractory follicular lymphoma patients with an EZH2 mutation as detected by an FDA approved test.
The FDA also approved the Cobas EZH2 Mutation Test by Roche as a companion diagnostic for tazemetostat.